$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-Q Financial Statement

#000110465912032225 Filed on May 03, 2012

Income Statement

Concept	2012 Q2	2012 Q1	2011 Q1
Revenue	$0.00	$147.0K	$1.100M
YoY Change	-100.0%	-86.64%	-72.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$2.600M	$2.700M
YoY Change	0.0%	-3.7%	-12.9%
% of Gross Profit
Research & Development	$11.25M	$12.07M	$9.436M
YoY Change	8.02%	27.87%	-7.49%
% of Gross Profit
Depreciation & Amortization	$300.0K	$230.0K	$439.0K
YoY Change	-25.0%	-47.61%	-15.58%
% of Gross Profit
Operating Expenses	$14.13M	$14.71M	$12.11M
YoY Change	5.77%	21.5%	-8.95%
Operating Profit	-$14.13M	-$14.57M	-$10.97M
YoY Change	17.7%	32.82%
Interest Expense	-$486.0K	-$486.0K	-$435.0K
YoY Change	-1.42%	11.72%	335.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.60M	-$15.10M	-$11.40M
YoY Change	16.8%	32.46%	22.58%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.60M	-$15.10M	-$11.40M
YoY Change	16.8%	32.46%	22.58%
Net Earnings / Revenue		-10272.11%	-1036.36%
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.125M	-$9.438M	-$9.500M
COMMON SHARES
Basic Shares Outstanding	57.64M shares	56.37M shares	42.01M shares
Diluted Shares Outstanding		56.37M shares	42.01M shares

Balance Sheet

Concept	2012 Q2	2012 Q1	2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.70M	$57.40M	$40.20M
YoY Change	-28.93%	42.79%	-30.57%
Cash & Equivalents	$25.59M	$34.55M	$17.37M
Short-Term Investments	$19.10M	$22.80M	$22.90M
Other Short-Term Assets	$800.0K	$600.0K	$500.0K
YoY Change	0.0%	20.0%	-50.0%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$45.50M	$58.00M	$40.80M
YoY Change	-28.57%	42.15%	-30.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.166M	$1.324M	$1.800M
YoY Change	-16.71%	-26.44%	-48.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$519.0K	$400.0K
YoY Change	0.0%	29.75%	100.0%
Total Long-Term Assets	$1.700M	$1.843M	$2.100M
YoY Change	-10.53%	-12.24%	-41.67%
TOTAL ASSETS
Total Short-Term Assets	$45.50M	$58.00M	$40.80M
Total Long-Term Assets	$1.700M	$1.843M	$2.100M
Total Assets	$47.20M	$59.84M	$42.90M
YoY Change	-28.05%	39.49%	-31.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.500M	$3.040M	$1.700M
YoY Change	75.0%	78.82%	13.33%
Accrued Expenses	$6.900M	$6.500M	$5.400M
YoY Change	18.97%	20.37%	-6.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.900M	$6.100M	$5.600M
YoY Change	154.84%	8.93%	366.67%
Total Short-Term Liabilities	$18.25M	$15.64M	$17.30M
YoY Change	19.31%	-9.57%	33.08%
LONG-TERM LIABILITIES
Long-Term Debt	$8.400M	$10.40M	$11.50M
YoY Change	-39.13%	-9.57%	2200.0%
Other Long-Term Liabilities			$1.000M
YoY Change			-82.14%
Total Long-Term Liabilities	$8.400M	$10.43M	$12.50M
YoY Change	-39.13%	-16.58%	104.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.25M	$15.64M	$17.30M
Total Long-Term Liabilities	$8.400M	$10.43M	$12.50M
Total Liabilities	$26.70M	$26.07M	$29.80M
YoY Change	-8.56%	-12.51%	55.21%
SHAREHOLDERS EQUITY
Retained Earnings		-$413.5M
YoY Change
Common Stock		$447.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.46M	$33.77M	$13.10M
YoY Change
Total Liabilities & Shareholders Equity	$47.16M	$59.84M	$42.90M
YoY Change	-28.1%	39.49%	-31.36%

Cashflow Statement

Concept	2012 Q2	2012 Q1	2011 Q1
OPERATING ACTIVITIES
Net Income	-$14.60M	-$15.10M	-$11.40M
YoY Change	16.8%	32.46%	22.58%
Depreciation, Depletion And Amortization	$300.0K	$230.0K	$439.0K
YoY Change	-25.0%	-47.61%	-15.58%
Cash From Operating Activities	-$13.10M	-$15.25M	-$12.84M
YoY Change	7.82%	18.77%	1.99%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	$147.0K	$10.00K
YoY Change	50.0%	1370.0%
Acquisitions
YoY Change
Other Investing Activities	$3.760M	-$13.17M	-$3.190M
YoY Change	-126.61%	312.85%
Cash From Investing Activities	$3.700M	-$13.32M	-$3.200M
YoY Change	-126.11%	316.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$28.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	440.0K	33.05M	2.100M
YoY Change	-98.74%	1473.81%	-92.03%
NET CHANGE
Cash From Operating Activities	-13.10M	-15.25M	-12.84M
Cash From Investing Activities	3.700M	-13.32M	-3.200M
Cash From Financing Activities	440.0K	33.05M	2.100M
Net Change In Cash	-8.960M	4.480M	-13.94M
YoY Change	-205.16%	-132.14%	-201.31%
FREE CASH FLOW
Cash From Operating Activities	-$13.10M	-$15.25M	-$12.84M
Capital Expenditures	-$60.00K	$147.0K	$10.00K
Free Cash Flow	-$13.04M	-$15.40M	-$12.85M
YoY Change	7.68%	19.82%	2.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34550000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2012Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	22840000	USD
CY2012Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	608000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	561000	USD
CY2012Q1	us-gaap	Assets Current AssetsCurrent	57998000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	40286000	USD
CY2012Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1324000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1407000	USD
CY2012Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	519000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	631000	USD
CY2012Q1	us-gaap	Assets Assets	59841000	USD
CY2011Q4	us-gaap	Assets Assets	42324000	USD
CY2012Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3040000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3467000	USD
CY2012Q1	snta	Accrued Contract Research Costs AccruedContractResearchCosts	4007000	USD
CY2011Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	2841000	USD
CY2012Q1	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	2530000	USD
CY2011Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	4594000	USD
CY2012Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	12000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	12000	USD
CY2012Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	6055000	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	4234000	USD
CY2012Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	447226000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	413196000	USD
CY2012Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2012Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-413481000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398430000	USD
CY2012Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15644000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15148000	USD
CY2012Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	11000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	14000	USD
CY2012Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	10416000	USD
CY2012Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10427000	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12402000	USD
CY2012Q1	us-gaap	Liabilities Liabilities	26071000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	27550000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	33770000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	14774000	USD
CY2012Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59841000	USD
CY2012Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49539808	shares
CY2012Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57639108	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49539808	shares
CY2012Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57639108	shares
CY2012Q1	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1) Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p></td></tr></table>
CY2011Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	51000	USD
CY2011Q1	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	1143000	USD
CY2011Q1	snta	Collaborative Revenues CollaborativeRevenues	1143000	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2012Q1	snta	Total Revenues TotalRevenues	147000	USD
CY2011Q1	snta	Total Revenues TotalRevenues	1143000	USD
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12066000	USD
CY2011Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9436000	USD
CY2011Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2673000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	14712000	USD
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	12109000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14565000	USD
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10966000	USD
CY2012Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-486000	USD
CY2011Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-435000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15051000	USD
CY2011Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11401000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56366992	shares
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56366992	shares
CY2011Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42008818	shares
CY2011Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42008818	shares
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15035000	USD
CY2011Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11395000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	827000	USD
CY2011Q1	us-gaap	Share Based Compensation ShareBasedCompensation	827000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	230000	USD
CY2011Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	439000	USD
CY2011Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-116000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47000	USD
CY2011Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	93000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-112000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-427000	USD
CY2011Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-234000	USD
CY2012Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	1166000	USD
CY2011Q1	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	742000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2064000	USD
CY2011Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2042000	USD
CY2011Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1142000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15254000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12839000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	22824000	USD
CY2011Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	14534000	USD
CY2012Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9650000	USD
CY2011Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	11342000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147000	USD
CY2011Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13321000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3202000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	28204000	USD
CY2011Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	190000	USD
CY2011Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2000000	USD
CY2012Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	151000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
CY2011Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	87000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	33050000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4475000	USD
CY2011Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-13938000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	501000	USD
CY2011Q1	us-gaap	Interest Paid InterestPaid	371000	USD
CY2011Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17372000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31310000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42324000	USD
CY2012Q1	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
CY2012Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2012Q1	dei	Document Type DocumentType	10-Q
CY2012Q1	dei	Document Period End Date DocumentPeriodEndDate	2012-03-31
CY2012Q1	dei	Amendment Flag AmendmentFlag	false
CY2012Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2012Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57639108	shares

Files In Submission

Name	View Source	Status
0001104659-12-032225-index-headers.html	Edgar Link	pending
0001104659-12-032225-index.html	Edgar Link	pending
0001104659-12-032225.txt	Edgar Link	pending
0001104659-12-032225-xbrl.zip	Edgar Link	pending
a12-8756_110q.htm	Edgar Link	pending
a12-8756_1ex10d1.htm	Edgar Link	pending
a12-8756_1ex10d2.htm	Edgar Link	pending
a12-8756_1ex31d1.htm	Edgar Link	pending
a12-8756_1ex31d2.htm	Edgar Link	pending
a12-8756_1ex32d1.htm	Edgar Link	pending
a12-8756_1ex5d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g87561kci001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20120331.xml	Edgar Link	completed
snta-20120331.xsd	Edgar Link	pending
snta-20120331_cal.xml	Edgar Link	unprocessable
snta-20120331_def.xml	Edgar Link	unprocessable
snta-20120331_lab.xml	Edgar Link	unprocessable
snta-20120331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2012 Q2 Form 10-Q Financial Statement

#000110465912032225 Filed on May 03, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2012 Q2 Form 10-Q Financial Statement

#000110465912032225 Filed on May 03, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl